A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

NCT05329051 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection
COVID-19

Interventions

BIOLOGICAL: SCTV01E
BIOLOGICAL: Comirnaty

Sponsor

Sinocelltech Ltd.